89bio (ETNB) News Today → A letter is coming from the 'Bureau of the Fiscal Service'. (From Stansberry Research) (Ad) Free ETNB Stock Alerts $8.63 -0.34 (-3.79%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 10:09 AM | marketbeat.com89bio (NASDAQ:ETNB) Rating Reiterated by Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and set a $29.00 price target on shares of 89bio in a research report on Friday.May 17 at 6:39 AM | americanbankingnews.comEvercore ISI Lowers 89bio (NASDAQ:ETNB) Price Target to $33.00May 16 at 1:25 PM | markets.businessinsider.comBuy Rating for 89bio on Pegozafermin’s Promise in Advanced NASH TrialsMay 16 at 8:56 AM | marketbeat.com89bio (NASDAQ:ETNB) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $29.00 price objective on shares of 89bio in a report on Thursday.May 16 at 2:42 AM | americanbankingnews.comFY2024 Earnings Estimate for 89bio, Inc. (NASDAQ:ETNB) Issued By Cantor FitzgeraldMay 15 at 6:02 PM | marketbeat.com89bio (NASDAQ:ETNB) Trading Up 5.5%89bio (NASDAQ:ETNB) Stock Price Up 5.5%May 15 at 9:33 AM | marketbeat.com89bio (NASDAQ:ETNB) Given New $33.00 Price Target at Evercore ISIEvercore ISI lowered their target price on shares of 89bio from $37.00 to $33.00 and set an "outperform" rating on the stock in a report on Wednesday.May 15 at 8:12 AM | marketbeat.com89bio, Inc. (NASDAQ:ETNB) to Post FY2024 Earnings of ($2.30) Per Share, Cantor Fitzgerald Forecasts89bio, Inc. (NASDAQ:ETNB - Free Report) - Stock analysts at Cantor Fitzgerald lowered their FY2024 earnings per share estimates for shares of 89bio in a report issued on Monday, May 13th. Cantor Fitzgerald analyst K. Kluska now expects that the company will earn ($2.30) per share for the year, doMay 15 at 12:59 AM | morningstar.com89bio Inc Ordinary SharesMay 14, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Hold Rating on 89bio (ETNB)May 14, 2024 | globenewswire.com89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated CirrhosisMay 14, 2024 | americanbankingnews.com89bio (NASDAQ:ETNB) Price Target Lowered to $29.00 at HC WainwrightMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for 89bio Amid Pegozafermin’s Clinical Advances and Market PotentialMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for 89bio Amid Promising Drug Candidate Progress and Strategic ReadinessMay 10, 2024 | finance.yahoo.com89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical TrialsMay 10, 2024 | marketbeat.com89bio (NASDAQ:ETNB) Announces Earnings Results89bio (NASDAQ:ETNB - Get Free Report) released its earnings results on Thursday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.08). During the same quarter in the previous year, the firm posted ($0.54) EPS.May 10, 2024 | globenewswire.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | marketbeat.com89bio (NASDAQ:ETNB) PT Lowered to $29.00HC Wainwright cut their price target on 89bio from $31.00 to $29.00 and set a "buy" rating on the stock in a research note on Friday.May 9, 2024 | msn.comETNB Stock Earnings: 89bio Misses EPS for Q1 2024May 9, 2024 | globenewswire.com89bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.com89bio to Participate in the BofA Securities 2024 Health Care ConferenceMay 2, 2024 | finance.yahoo.com89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASHMay 2, 2024 | globenewswire.com89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASHApril 29, 2024 | marketbeat.comabrdn plc Takes Position in 89bio, Inc. (NASDAQ:ETNB)abrdn plc acquired a new stake in shares of 89bio, Inc. (NASDAQ:ETNB - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 214,192 shares of the company's stock, valued at approximately $2,393,000.April 24, 2024 | investing.comBofA raises 89bio to stock buy amid MASH outlookApril 22, 2024 | finance.yahoo.com89bio, Inc. (ETNB) Stock Historical Prices & Data - Yahoo FinanceApril 22, 2024 | marketbeat.com89bio (NASDAQ:ETNB) Shares Gap Up to $9.0889bio (NASDAQ:ETNB) Shares Gap Up to $9.08April 22, 2024 | marketbeat.comBank of America Reaffirms "Buy" Rating for 89bio (NASDAQ:ETNB)Bank of America reissued a "buy" rating and set a $30.00 target price on shares of 89bio in a report on Monday.April 22, 2024 | marketbeat.comFederated Hermes Inc. Sells 167,035 Shares of 89bio, Inc. (NASDAQ:ETNB)Federated Hermes Inc. trimmed its position in shares of 89bio, Inc. (NASDAQ:ETNB - Free Report) by 7.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,962,566 shares of the company's stock after selling 167,035 shaApril 17, 2024 | globenewswire.com89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of DirectorsApril 11, 2024 | marketbeat.com89bio (NASDAQ:ETNB) Stock Price Down 4.2%89bio (NASDAQ:ETNB) Stock Price Down 4.2%April 9, 2024 | marketbeat.comVanguard Group Inc. Increases Stock Holdings in 89bio, Inc. (NASDAQ:ETNB)Vanguard Group Inc. boosted its stake in 89bio, Inc. (NASDAQ:ETNB - Free Report) by 4.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,525,782 shares of the company's stock after acquiring an additional 155,841 shares during the quarter. Vanguard GApril 5, 2024 | globenewswire.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 5, 2024 | marketbeat.com89bio (NASDAQ:ETNB) Earns Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and issued a $29.00 price target on shares of 89bio in a research note on Friday.April 3, 2024 | finance.yahoo.com89bio Inc CEO Rohan Palekar Sells 52,718 SharesApril 1, 2024 | marketbeat.com89bio (NASDAQ:ETNB) Shares Down 6.8% 89bio (NASDAQ:ETNB) Trading Down 6.8%April 1, 2024 | marketbeat.com89bio, Inc. (NASDAQ:ETNB) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of 89bio, Inc. (NASDAQ:ETNB - Get Free Report) have received an average rating of "Moderate Buy" from the six research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommeMarch 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for 89bio’s Pegozafermin: A Promising NASH Treatment with Strong Regulatory EndorsementsMarch 27, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)March 27, 2024 | globenewswire.com89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated CirrhosisMarch 20, 2024 | marketbeat.com89bio (NASDAQ:ETNB) Trading Down 4.3%89bio (NASDAQ:ETNB) Shares Down 4.3%March 16, 2024 | insidertrades.com89bio, Inc. (NASDAQ:ETNB) Director Buys $20,722,500.00 in StockMarch 16, 2024 | finance.yahoo.comETNB Apr 2024 12.500 putMarch 15, 2024 | marketbeat.com89bio (NASDAQ:ETNB) Trading Up 3.3%89bio (NASDAQ:ETNB) Shares Up 3.3%March 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Intuitive Surgical (ISRG)March 14, 2024 | marketbeat.com89bio (NASDAQ:ETNB) Stock Price Down 7.5%89bio (NASDAQ:ETNB) Stock Price Down 7.5%March 12, 2024 | globenewswire.com89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with FibrosisMarch 10, 2024 | 247wallst.comBuffett Loads Up on This Stock Again, Plus CEO Insider BuyingMarch 8, 2024 | globenewswire.com89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 7, 2024 | msn.comInsider Trading: Director Boosts Stake in 89bio (NASDAQ:ETNB) Stock Get 89bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter. Email Address A letter is coming from the "Bureau of the Fiscal Service". (Ad)Is your bank next? A powerful new trend is spreading like wildfire inside the US financial system. At least 41 banks are already involved. But the Federal Reserve predicts that number will grow fast. See if your bank is involved right here. ETNB Media Mentions By Week ETNB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ETNB News Sentiment▼-0.050.52▲Average Medical News Sentiment ETNB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ETNB Articles This Week▼193▲ETNB Articles Average Week Get 89bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Praxis Precision Medicines News OPKO Health News ALX Oncology News Zentalis Pharmaceuticals News Arcutis Biotherapeutics News ARS Pharmaceuticals News ABIVAX Société Anonyme News Ocular Therapeutix News Immunome News Tyra Biosciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ETNB) was last updated on 5/18/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceThe Presidential candidate you should REALLY be worried aboutStansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressWhat’s Really Next for America…Porter & CompanyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
